C – reactive protein in relation to fasting glucose levels in obese or overweight men
Paper Details
C – reactive protein in relation to fasting glucose levels in obese or overweight men
Abstract
C-reactive protein (CRP) as an inflammatory cytokine is associated with insulin resistance, obesity and type II diabetes. The purpose of this study was to examine the relation of CRP to glucose concentration in adult obese or overweight men and to compare this inflammatory cytokine between normal weight and obese or overweight men. Participants included fourteen non athletes sedentary overweight or obese (30 ≤ BMI ≤ 36) and ten normal weight (20 ≤ BMI ≤ 26) men aged 34 – 41 year. Fasting blood samples were taken after an overnight fast to determine glucose, insulin, and C – reactive protein in two groups. Independent T test used to compare al variables between two groups and Pearson correlation method was used to relation between them. Fasting serum CRP concentrations were higher in obese or overweight subjects than in normal weight men (2205 +/- 805 versus 375 +/- 181 ng/ml, P = 0.005). Serum CRP was positively related with glucose concentration in obese group (p = 0.001, r = 0.77). Based on these finding, we can say serum CRP affect directly glucose concentration in obese individuals.
Azadbakht L, Atabak S, Esmaillzdeh A. 2008. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care 31, 648–54.
Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. 2003. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. American Journal of Physiology – Endocrinology and Metabolism 285, 527–33.
Cook DG, Mendall MA, Whincup PH, CareyIM, Ballam L, Morris JE. 2000. C-reactive proteinconcentration in children: relationship to adiposityand other cardiovascular risk factors. Atherosclerosis 149(1), 139-150.
Das UN, Fams MD. 2001. Is obesity an inflammatory condition? Nutrition 17(11-12), 953-966.
De Ferranti S, Rifai N. 2002. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clinica Chimica Acta 317, 1-15.
Ebrahim R, Hassan E, Hossein A, Vajihe C, Armin R. 2012. Armin Razi Evaluation of High-Sensitivity C-Reactive Protein in Acute Asthma Tanaffos 11(1), 32-37.
Festa A, D’Agostino RJR, Howard G, Mykkanen L, Tracy RP, Haffner SM. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42-47.
Fishcher CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. 2007. Plasma levels ofinterleukin-6 and C-reactive protein are associatedwith physical inactivity independent of obesity. Journal of Medical Science in Sports 17, 580-587.
Ford ES. 1999. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22, 1971-77.
Frohlich M, Imhof A, Berg G. 2000. Association between C-reactive protein and features of themetabolic syndrome: a population-based study. Diabetes Care 23, 1835-1839.
Julia W, Karen C, Javier R, Ascension M. 2010. Role of physical activity on immune function Physical activity, exercise and low-grade systemic inflammation. Proceedings of the Nutrition Society 69, 400–406.
Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K. 2006. The Relationships of Plasma Adiponectin with a Favorable Lipid Profile, Decreased Inflammation, and Less Ectopic Fat Accumulation Depend on Adiposity. Clinical Chemistry 52(10), 1934-42.
King DE, Mainous AG III, Egan BM, Woolson RF, Geesey ME. 2005. Fiber and C-reactive protein in diabetes, hypertension and obesity. Diabetes Care 28, 1487–9.
LaMonte MJ, Durstine JL, Yanowitz FG, Lim T, DuBose KD, Davis P. 2002. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation (106), 403-406.
Nicklas BJ, You T, Pahor M. 2005. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. Canadian Medical Association Journal 172, 1199–209.
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H. 2003. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107, 671–4.
Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas E, Stefanadis C. 2008. Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study. Vascular Medicine 13, 113–21.
Pearson TA, Mensah GA, Alexander RW. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511.
Pedersen BK. 2006. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays in Biochemistry 42, 105–117.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3), 327-34.
Ridker PM. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347, 1557–1565.
Schultz DR, Arnold PI. 1990. Properties of four acute phase proteins: C-reactive protein, serum amyloid a protein, a1-acid glycoprotein and fibrinogen. Seminars in Arthritis and Rheumatism 20, 129–47.
Subodh V, Paul ES, Paul MR. 2005. C-reactive protein comes of age. Nature Clinical Practice Cardiovascular Medicine’s 2(1), 29-36.
Tice JA. 2003. The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S . Women. American Journal of Medicine 114, 199–205.
Torabi Mohsen, Baghery Hadi, Falah Ahmad, 2014. C – reactive protein in relation to fasting glucose levels in obese or overweight men. J. Biodiv. Environ. Sci., 4(1), 250-255.
Copyright © 2014 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.